This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacists led to decreased rates of adverse drug reactions (ADRs) in a Hem/Onc clinic.
Dordaviprone data: https://doi.org/10.1200/jco.23.01134
Alabassi AK, et al. Role of a designated pharmacist in reducing adverse drug reacti ... Show More
Jun 2021
Review Series on Platelets and Cancer
Platelets are critical for hemostasis and thrombosis, but recent research highlights their role in many other processes, including inflammation, wound healing, and lymphangiogenesis. In this episode, Drs. José López, Elisabeth Battinelli, Craig Williams, and Owen McCarty discuss ... Show More
35m 27s
Aug 14
11: Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
The latest Oncology Decoded discussion with Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and ... Show More
41m 45s